Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 14/20 | 0.56 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3621873 | 0.93 | FDPS (0.59) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL474190 | 0.91 | GGPS1 (0.63) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL8645576 | 0.91 | GGPS1 (0.63) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL20484187 | 0.91 | GGPS1 (0.63) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL4735538 | 0.91 | GGPS1 (0.63) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL9463628 | 0.91 | GGPS1 (0.63) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL6229883 | 0.91 | GGPS1 (0.63) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL21879326 | 0.91 | GGPS1 (0.63) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL3861125 | 0.86 | FDPS (0.61) | FDPSGGPS1LPAR1LPAR3SMPD1 | |
| SCHEMBL3295661 | 0.86 | FDPS (0.61) | FDPSGGPS1LPAR1LPAR3SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835542-B2 | Nucleating agent and thermoplastic compositions comprising the same | MILLIKEN & COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2424929-B1 | NUCLEATING AGENT AND THERMOPLASTIC COMPOSITIONS COMPRISING THE SAME | MILLIKEN & CO (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2424929-A1 | NUCLEATING AGENT AND THERMOPLASTIC COMPOSITIONS COMPRISING THE SAME | Milliken & Company (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120043692-A1 | NUCLEATING AGENT AND THERMOPLASTIC COMPOSITIONS COMPRISING THE SAME | CONNOR DANIEL M (US) | 2012-02-23 | — | — | US | disclosed |
| US-8044091-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2256124-A1 | Phospho-indoles as HIV inhibitors | IDENIX Pharmaceuticals, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010126559-A1 | NUCLEATING AGENT AND THERMOPLASTIC COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-1961757-B1 | Phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS LLC | 2009-06-25 | — | — | US | disclosed |
| US-7534809-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1799696-B1 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1961757-A1 | Phosphoindoles as HIV inhibitors | IDENIX Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1799696-A2 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006054182-A9 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX CAYMAN LTD | 2006-08-17 | — | — | WO | disclosed |
| WO-2006054182-A2 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060074054-A1 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074054-A1 | Phospho-indoles as HIV inhibitors | IDO1, PPP5C, INMT | FDPS 1669/4885GGPS1 1787/4885LPAR1 2197/4885 |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDO1, PPP5C, INMT | FDPS 1669/4885GGPS1 1787/4885LPAR1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.